Coffee-Ground Emesis in a Patient on Dual Antiplatelet Therapy
A 68-year-old man with a drug-eluting stent placed 6 weeks ago presents with two episodes of coffee-ground emesis and melena over 24 hours. He takes aspirin 81 mg daily plus ticagrelor, atorvastatin, and ibuprofen 400 mg three times daily for knee osteoarthritis. BP 104/62, HR 108, orthostatic. Hemoglobin 8.4 g/dL from a baseline of 13.9. BUN 46, creatinine 1.1. He is admitted and resuscitated with crystalloid; a type and screen is sent. Cardiology is reached and states the stent is 'too fresh to stop everything.' The patient asks whether he can just go home after 'some fluids.'
1. How should you sequence resuscitation, risk stratification, and endoscopy, and what is the target timing of endoscopy here?
Read the worked answer
Resuscitation first, then risk-stratify, then scope - but do not let resuscitation become indefinite delay.
- Hemodynamic stabilization: two large-bore IVs, crystalloid, crossmatch. Transfuse to a restrictive threshold - typically hemoglobin <7 g/dL, but <8 g/dL in known cardiovascular disease, which this patient has. Over-transfusion risks volume overload and may worsen bleeding by raising BP.
- Risk stratification: calculate Glasgow-Blatchford (BUN 46, Hb 8.4, HR >100, melena, systolic <110 - this is high risk) and pre-endoscopy Rockall. High GBS mandates inpatient care and non-endoscopic management while awaiting scope.
- Pre-endoscopy pharmacotherapy: IV proton pump inhibitor bolus then infusion is appropriate for suspected ulcer bleeding, though it does not replace endoscopic hemostasis.
- Timing: For hemodynamically unstable or actively bleeding patients, endoscopy within 12 hours after resuscitation. For stabilized patients without exsanguination, within 24 hours is standard; very early (<6 h) endoscopy has not shown mortality benefit over 24 h in stable patients. This man is tachycardic and orthostatic, so he falls into the earlier (≤12 h) window once resuscitated.
- Antithrombotic management is a team decision made in parallel, not after the scope.
2. Cardiology says the stent cannot be left unprotected. How do you manage aspirin, ticagrelor, and ibuprofen around endoscopy, and what do you tell the patient about the NSAID?
Read the worked answer
Aspirin should be continued. Withholding aspirin in a patient with a recent drug-eluting stent increases stent thrombosis risk, and aspirin does not prevent endoscopic hemostasis. Guidelines support continuing low-dose aspirin through an acute GI bleed, especially with recent stenting.
The P2Y12 inhibitor (ticagrelor) is the lever to pull. For a high-risk bleeding lesion, it is reasonable to hold ticagrelor for ~3–5 days after endoscopic hemostasis is achieved, in consultation with cardiology, then resume. This is a risk-balance decision: bleeding risk versus stent thrombosis. Because the stent is only 6 weeks old, this decision should be documented jointly with cardiology rather than made unilaterally. If endoscopy shows a clean-based ulcer or low-risk stigmata, the interruption can be shorter or avoided.
Ibuprofen must be stopped permanently. NSAIDs are the proximate cause and dramatically increase rebleeding and ulcer risk; continuing them negates any endoscopic therapy. Offer acetaminophen and non-pharmacologic osteoarthritis care, and consider topical or intra-articular therapy. If an NSAID is ever unavoidable in a patient with cardiovascular disease, a COX-2 selective agent plus a PPI is the least-bad option - but not here, not now.
Counsel the patient explicitly: going home after fluids is not safe - he is high-risk by GBS, has a fresh stent, and needs endoscopic diagnosis and hemostasis. Also place him on a PPI after hemostasis and test/treat H. pylori.
3. Endoscopy reveals a 12-mm posterior duodenal bulb ulcer with a non-bleeding visible vessel. What endoscopic therapy do you apply, and what is your post-procedure plan?
Read the worked answer
Lesion: a non-bleeding visible vessel carries a high rebleeding risk (~40–50% untreated) and warrants endoscopic therapy even without active spurting.
Endoscopic therapy:
- Injection of dilute epinephrine (1:10,000) to slow bleeding and improve visualization, followed by a second modality - either bipolar/thermal coagulation or, preferably, through-the-scope clips. Combination therapy (epinephrine + a mechanical or thermal method) reduces rebleeding, surgery, and mortality versus epinephrine alone. Epinephrine monotherapy is inadequate.
- Avoid excessive thermal energy on the posterior bulb given proximity to the gastroduodenal artery.
Post-procedure:
- High-dose PPI: IV bolus then continuous infusion (or intermittent high-dose oral) for 72 hours, then oral PPI.
- H. pylori: biopsy or urea breath/stool antigen and treat if positive - eradication is the single most important intervention to prevent recurrent ulcer bleeding.
- Antithrombotics: resume aspirin immediately; discuss timing of ticagrelor resumption with cardiology (typically after 3–5 days if hemostasis is secure).
- Monitoring: serial hemoglobin, watch for rebleeding; a second look is not routine but is considered if rebleeding occurs.
- Disposition: continue inpatient monitoring; do not discharge on the day of hemostasis in a patient with this risk profile.